Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit Jan Schuurhuis(Amsterdam University Medical Centers), Gert J. Ossenkoppele(Dutch Cancer Society), Gail J. Roboz(Cornell University), Francis Lacombe, Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Brent L. Wood(University of Southern California), Claude Preudhomme(Centre Hospitalier Universitaire de Lille), Sylvie Freeman(University of Birmingham), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Luca Maurillo(University of Rome Tor Vergata), Torsten Haferlach(Martin Luther Christian University), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Bert A. van der Reijden(Radboud University Nijmegen), Michael Heuser(Martin Luther University Halle-Wittenberg), Konstanze Döhner(University Hospital Ulm), Christopher S. Hourigan(National Heart Lung and Blood Institute), Marie C. Béné(Centre Hospitalier Universitaire de Nantes), Jacqueline Cloos(Vrije Universiteit Amsterdam), Paresh Vyas(University of Oxford), David Grimwade(King's College School), Francesco Buccisano(University of Rome Tor Vergata), Adriano Venditti(University of Rome Tor Vergata), Christian Thiede(University Hospital Carl Gustav Carus)
Cited by 1,026
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k